Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Organ failure due to fatty liver - 24/09/2020 AdobeStock_9729015_SciePro_Leber_Mensch.jpg

    HepaRegeniX develops an active substance for liver regeneration

    When the liver stops regenerating on its own, it might be possible in future for doctors to intervene with a chemical agent. Tübingen-based HepaRegeniX GmbH is developing a promising candidate with the aim of improving the treatment of both acute and chronic liver failure.

    https://www.gesundheitsindustrie-bw.de/en/article/news/heparegenix-develops-active-substance-liver-regeneration
  • Article - 13/02/2012 Photo of Dr. Suzanne Kadereit

    Suzanne Kadereit: assessing nanotoxicity using stem cells

    Nanotoxicity has become the subject of concern because of increasing toxic effects of nanomaterials on living organisms. However such effects are difficult to detect in people. In an interview with BIOPRO Baden-Württemberg Dr. Susanne Kadereit biologist at the University of Konstanz reports about her work involving the development of a human in-vitro system that enables the more effective assessment of the toxicity of nanoparticles.

    https://www.gesundheitsindustrie-bw.de/en/article/news/suzanne-kadereit-assessing-nanotoxicity-using-stem-cells
  • Article - 29/07/2011 14959_de.jpg

    Labor Dr. Merk und Kollegen - Viruses under control

    It is difficult to imagine how Ochsenhausen-based Labor Dr. Merk und Kollegen (LMK) would be able to develop, produce and test medical products for bacterial and viral contaminations without using cell cultures. The medium-sized company also produces viruses for testing and has stored more than 80 different viruses – enveloped and non-enveloped ones, animal and human pathogens – at -80˚C.

    https://www.gesundheitsindustrie-bw.de/en/article/news/labor-dr-merk-und-kollegen-viruses-under-control
  • Article - 09/02/2008

    A better alternative from the perspective of embryo protection

    Karin Bundschuh of BIOPRO Baden-Württemberg asked Dr. Jens Clausen how these developments should be viewed from an ethical perspective. The bioethicist spent many years studying the status of embryos the ethics of cloning and stem cell research.

    https://www.gesundheitsindustrie-bw.de/en/article/news/a-better-alternative-from-the-perspective-of-embryo-protection
  • Article - 29/08/2011 Research group led by Dr. Ute Schepers (left) at KIT.

    Ute Schepers – the therapeutic potential of small RNAs and molecular transporters

    Small RNAs can specifically interfere with cellular mechanisms; or more precisely, with the cells’ protein biosynthesis machinery. Scientists have therefore decided to exploit this potential by using small RNAs against cancer cells or cells damaged in other ways. But the question arises as to how the small RNAs can reach the site where their role is to prevent the generation of dangerous proteins. Dr. Ute Schepers and her team from the Karlsruhe…

    https://www.gesundheitsindustrie-bw.de/en/article/news/ute-schepers-the-therapeutic-potential-of-small-rnas-and-molecular-transporters
  • Article - 14/06/2011 14497_de.jpg

    Retinitis pigmentosa: a new form of cell death

    What form of cell death do the photoreceptors of people suffering from retinitis pigmentosa undergo and how can their degeneration be prevented or delayed with pharmaceutical substances? Dr. Paquet-Durand from the Institute for Ophthalmic Research in Tübingen is working to resolve these questions.

    https://www.gesundheitsindustrie-bw.de/en/article/news/retinitis-pigmentosa-a-new-form-of-cell-death
  • Article - 21/03/2016 Schematic presentation before and after treatment showing the effect of the therapy. Blood vessel density improves considerably.

    Shock wave therapy gives hope to many men

    Although the approval of vasodilatory drugs made available an effective medicine for treating erectile dysfunction, not all men respond to this type of treatment. MTS Medical UG from Konstanz has developed a therapeutic device that means that these men can now get help too. What's more, the device has no adverse health effects.

    https://www.gesundheitsindustrie-bw.de/en/article/news/shock-wave-therapy-gives-hope-to-many-men
  • Article - 30/06/2009 Following the treatment of a patient with cytochrome P450-inducing anti-epileptic drugs (in this case, carbamazepin), the quantity of androgen receptors (green) considerably increases.

    More targeted treatment of the brain network

    “Casting out the demons with the ruler of the demons” – is what the majority of neuroactive drugs still do. A group under the leadership of Dr. Ralf Meyer at the University Medical Centre in Freiburg is investigating why substances used to treat epilepsy or depression have a negative effect on many patients. Their research shows that the drugs interact with the hormonal system, resulting in undesired side effects. Meyer and his team of…

    https://www.gesundheitsindustrie-bw.de/en/article/news/more-targeted-treatment-of-the-brain-network
  • Article - 07/03/2011 Prof. Dr. Thomas Brunner

    Thomas Brunner: steroid synthesis in the intestine

    A research team led by Prof. Dr. Thomas Brunner at the University of Konstanz has found out that intestinal epithelial cells are able to synthesise anti-inflammatory steroids glucocorticoids following immunological stress which makes a considerable contribution to the maintenance of local immune homoeostasis. Brunner plans to use his findings to develop a therapeutic approach for the treatment of inflammatory bowel diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/news/thomas-brunner-steroid-synthesis-in-the-intestine
  • Article - 15/08/2008

    Health research with microsystems

    The NMI Natural and Medical Sciences Institute in Reutlingen organised its biannual MEA conference from 8 to 11 July 2008. More than 200 developers and microelectrode array users from 18 countries came together in Reutlingen to present their latest developments and results.

    https://www.gesundheitsindustrie-bw.de/en/article/news/health-research-with-microsystems
  • Article - 19/06/2017 The photo shows the scientists in front of a computer screen with green cell cultures.

    Eric Gottwald: innovative 3D cell culture systems for pharmaceutical testing

    Realistic alternatives to animal testing are more in demand than ever, especially in the drug development field. One possible solution is 3D cell cultures that possess the characteristics of the tissue from which they originate. Such systems were already developed at the Karlsruhe Institute of Technology (KIT) many years ago. Due to the huge demand for such systems, Prof. Dr. Eric Gottwald and two of his colleagues founded a company called…

    https://www.gesundheitsindustrie-bw.de/en/article/news/eric-gottwald-innovative-3d-cell-culture-systems-for-pharmaceutical-testing
  • Article - 02/02/2009

    CureVac enters premier biotech league with new cancer vaccine

    At present active immunotherapy seems to produce the best results in the treatment of cancer. The Tübingen-based biotech company CureVac is now hoping to achieve a breakthrough in cancer therapy with a worldwide unique vaccine. The first clinical trials have recently commenced.

    https://www.gesundheitsindustrie-bw.de/en/article/news/curevac-enters-premier-biotech-league-with-new-cancer-vaccine
  • Article - 18/04/2008

    Better bypass with gene therapy?

    Almost half of the veins transplanted to restore blood flow in the heart become clogged again within ten years after surgery. Gene therapy pre-treatment of the vein fragments that prevents the muscle cells from entering the vascular wall might decrease the risk of this happening.

    https://www.gesundheitsindustrie-bw.de/en/article/news/better-bypass-with-gene-therapy
  • Article - 04/04/2011 Prof. Dr. Alexander Bürkle, Dr. María Moreno-Villanueva from the University of Konstanz

    Technical innovations for better diagnostics

    The quantitative detection of DNA single-strand breaks is of great importance for many areas of biomedical research and diagnostics. The Fluorescence-detected Alkaline DNA Unwinding FADU assay assists in the investigation of mechanisms of DNA damage and repair following DNA strand breaks upon exposure to chemicals. Prof. Alexander Bürkle and his team at the University of Konstanz have automated and optimised the original FADU assay which was…

    https://www.gesundheitsindustrie-bw.de/en/article/news/technical-innovations-for-better-diagnostics
  • Article - 21/07/2014 Schematic representation of multi-scale modelling: images of a molecule, cell, lung tissue and whole body, all connected with each other by arrows.<br />

    Predicting the efficiency of cancer drugs using mathematical models

    A research consortium was established at the Stuttgart Research Center Systems Biology SRCSB at the University of Stuttgart in January 2013 with the goal of establishing models that help predict the action of targeted therapeutics. The scientists combine molecular biology experiments with complex mathematical models in order to achieve a holistic understanding of disease and therapy.

    https://www.gesundheitsindustrie-bw.de/en/article/news/predicting-the-efficiency-of-cancer-drugs-using-mathematical-models
  • Article - 28/01/2010 10612_de.jpg

    Liver cell transplantation for the treatment of innate urea cycle defects

    Liver transplantation is the only life-saving therapy available to patients suffering from genetic defects of the urea cycle. However, newborns cannot be transplanted with a donor liver. The injection of liver cell suspensions into the liver of sick babies through the portal vein can substitute the lack of enzyme activity, hence preventing brain damage until such time as liver transplantation becomes possible.

    https://www.gesundheitsindustrie-bw.de/en/article/news/liver-cell-transplantation-for-the-treatment-of-innate-urea-cycle-defects
  • Article - 21/05/2012 17201_de.jpg

    Interactions between the genome and the environment

    Parental neglect appears to lead to epigenetic changes in children, which result in behavioural problems in later years. This is one issue amongst the many that were addressed at the colloquium “Gene und Umwelt – Wie wir werden, was wir sind” (Genes and the environment – how we become what we are) recently organized by the Daimler and Benz Foundation in Berlin.

    https://www.gesundheitsindustrie-bw.de/en/article/news/interactions-between-the-genome-and-the-environment
  • Article - 13/09/2010 Chemical formula of ifosfamide.

    Molecules adapted to the environment

    For many years Prof. Dr. Klaus Kümmerer from the University Medical Centre Freiburg has been investigating how the chemical structures of drugs and other chemicals can be modified in order to enable them to be degraded more quickly in rivers and soils. There has to be a new way of thinking said Kümmerer going on to add the appropriate methods are already in place.

    https://www.gesundheitsindustrie-bw.de/en/article/news/molecules-adapted-to-the-environment
  • Article - 14/12/2009 10386_de.jpg

    Clever surveillance system keeps yeast in check

    The spectrum of human diseases (mycoses) caused by fungi ranges from trivial nail infections to life-threatening systemic infections. The latter are mainly caused by Candida albicans. The dermatologist Prof. Dr. med. Martin Schaller from Tübingen is investigating how this fungus, which is actually part of the normal microbial flora of humans, becomes a pathogen. At the same time, he is looking into the role the patient’s immune system plays in…

    https://www.gesundheitsindustrie-bw.de/en/article/news/clever-surveillance-system-keeps-yeast-in-check
  • Article - 10/02/2009 08013_de.jpg

    Janine Reis – improving the acquisition of motor skills

    Putting a teaspoon of sugar into a cup of coffee would appear to be a very trivial action. However the coordination of hand and fingers becomes a virtually insurmountable challenge for people who have suffered a stroke. Dr. Janine Reis assistant doctor and researcher in the Department of Neurology at the Freiburg Medical School is investigating ways to improve the acquisition of fine motor skills.

    https://www.gesundheitsindustrie-bw.de/en/article/news/janine-reis-improving-the-acquisition-of-motor-skills
  • Article - 21/12/2016 Signatope GmbH’s founding team (from left to right) Prof. Dr. Hugo Hämmerle, Dr. Oliver Pötz, Dr. Hannes Planatscher, Dr. Octavian Schatz and Dr. Thomas Joos.

    For all types of tests: Signatope’s biomarker assays

    Signatope is a new biotech company that has been offering innovative biomarker assays for application in drug discovery since August 2016. The company’s assays can be used in all phases of drug development to detect potential adverse drug effects on the kidneys, liver and other organs in any species whatsoever using minute amounts of sample.

    https://www.gesundheitsindustrie-bw.de/en/article/news/for-all-types-of-tests-signatopes-biomarker-assays
  • Expert interview - 08/08/2018 Das Bild zeigt das Brustbild des ALS-Forschers, und Ärztlichen Direktors der Neurologischen Klinik der Uni Ulm, Prof. Albert Ludolph. Der Neurologe ist Sprecher des DZNE-Standorts Ulm.

    Ludolph: diagnosing and treating neurodegenerative disorders

    Ulm has long been a world leader in diagnosing and treating rare neurological disorders, notably amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Huntington's disease (HD). We spoke with Professor Albert C. Ludolph, spokesperson for the Ulm DZNE site, medical director of the Clinic for Neurology at the RKU (University and Rehabilitation Clinics of Ulm) and world-renowned ALS researcher.

    https://www.gesundheitsindustrie-bw.de/en/article/news/ludolph-diagnosing-and-treating-neurodegenerative-disorders
  • Dossier - 25/07/2011 Biberach-based Boehringer Ingelheim produces biopharmaceuticals on the basis of cell cultures. Here, the inoculation of cell cultures is shown. This is the first step in industrial-scale cell culture.

    Cell culture technology: it all started with frog nerve fibres

    The history of cell culture technology is closely connected with cell biology and the discoveries made in the field of cell biology. Ever since the study of science became a professional activity, researchers have been trying to keep cells and tissues alive outside organisms for purposes of investigation.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/cell-culture-technology-it-all-started-with-frog-nerve-fibres
  • Press release - 30/09/2011 15269_de.jpg

    Blood Vessels from Your Printer

    Researchers have been working at growing tissue and organs in the laboratory for a long time. These days, tissue engineering enables us to build up artificial tissue, although science still hasn’t been successful with larger organs. Now, researchers at Fraunhofer are applying new techniques and materials to come up with artificial blood vessels in their BioRap project that will be able to supply artificial tissue and maybe even complex organs in…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/blood-vessels-from-your-printer
  • Article - 17/05/2016 Schematic of the entire chip and an amplified sector showing the central area of the square chip along with the round seeding areas and microchannels.

    Innovative biochip for discovering drugs for treating neuronal conditions

    Parkinson’s, Alzheimer’s and epilepsy are three prominent examples of neuronal conditions (disorders affecting the nerve cells) for which drugs for treatment are intensively sought. Paolo Cesare from the NMI in Reutlingen has developed an innovative 3D system for testing drugs that does not require animal testing. In 2015, the MEAFLUIT system was awarded first prize in BioRegio STERN Management GmbH's Science2Start idea competition.

    https://www.gesundheitsindustrie-bw.de/en/article/news/innovative-biochip-for-discovering-drugs-for-treating-neuronal-conditions

Page 3 / 4

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2022
Website address: https://www.gesundheitsindustrie-bw.de/en/search